Principal Scientist, Integrated Computational and Experimental Inflammation Discovery
What You Will Do
Combine experimental and computational strategies to accelerate discovery and development of innovative therapies. Apply wet-lab biology expertise and AI/ML-driven computational and agentic research approaches to enable human-data-driven understanding of disease mechanisms and therapeutic opportunities.
Key Responsibilities
- Continuously apply computational, agentic, and other AI-driven approaches to generate mechanistic insights, refine therapeutic hypotheses, and guide experimental design.
- Design, execute, analyze, and interpret studies to investigate disease mechanisms and test therapeutic hypotheses.
- Generate high-quality experimental data to support target identification, validation, and progression of Inflammation research programs.
- Integrate experimental findings with published literature, human genetics, clinical observations, and other data sources to develop mechanistic insights and inform scientific decision-making.
- Participate in scientific discussions, target reviews, and portfolio evaluations with data-driven insights and recommendations.
- Present findings and recommendations to project teams and governance/forums.
- Maintain accurate documentation and contribute to knowledge-sharing.
- Embrace and contribute to a culture of scientific curiosity, collaboration, continuous learning, and operational excellence.
Basic Qualifications
- PhD
OR PharmD
OR MD (and relevant post-doc where applicable) with 2 years industry experience in Inflammation/Immunology
OR Masterβs with 5 years industry experience in Inflammation/Immunology
OR Bachelorβs with 7 years industry experience in Inflammation/Immunology
Preferred Qualifications
- Experience in highly collaborative, matrixed research environments.
- Ability to balance scientific rigor with urgency and adaptability.
- Commitment to teamwork, knowledge sharing, and continuous improvement.
Application instructions
- Apply via careers.amgen.com. Application acceptance anticipated until July 31 (may continue beyond if needed).